(Q44346297)

2 December 2017

title

Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone (English)

1 reference

2 December 2017

0 references

1 reference

1 reference

Vanitha Sekar

1

1 reference

2 December 2017

Frank Tomaka

2

1 reference

2 December 2017

Eric Lefebvre

3

1 reference

2 December 2017

Martine De Pauw

4

1 reference

2 December 2017

Tony Vangeneugden

5

1 reference

2 December 2017

Wim van den Brink

6

1 reference

2 December 2017

Richard Hoetelmans

7

1 reference

2 December 2017

publication date

26 April 2010

1 reference

The Journal of Clinical Pharmacology

2 December 2017

published in

1 reference

2 December 2017

volume

51

1 reference

2 December 2017

issue

2

1 reference

2 December 2017

page(s)

271-278

1 reference

Hepatitis C and HIV infections: implications for clinical care in injection drug users

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

HIV drug interactions: the good, the bad, and the other.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Actual and potential drug interactions associated with methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Pharmacokinetic drug interactions of synthetic opiate analgesics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Pharmacokinetic interactions between buprenorphine and antiretroviral medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

Increased (R)-Methadone Plasma Concentrations by Quetiapine in Cytochrome P450s and ABCB1 Genotyped Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010365558

21 January 2018

Identifiers

DOI

10.1177/0091270010365558

1 reference

2 December 2017

1 reference